We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02367781
First Posted: February 20, 2015
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hoffmann-La Roche
  Purpose
This randomized Phase III, multicenter, open-label study is designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel compared with treatment with carboplatin+nab-paclitaxel in chemotherapy-naive participants with Stage IV non-squamous NSCLC. Participants will be randomized in a 2:1 ratio to Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) or Arm B (Nab-Paclitaxel+Carboplatin).

Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody Drug: Carboplatin Drug: Nab-Paclitaxel Drug: Pemetrexed Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) [ Time Frame: Baseline until disease progression or death, whichever occurs first (up to approximately 31 months) ]
  • Overall Survival (OS) [ Time Frame: Baseline until death (up to approximately 31 months) ]

Secondary Outcome Measures:
  • Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 [ Time Frame: Baseline until disease progression or death, whichever occurs first (up to approximately 41 months) ]
  • Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 [ Time Frame: From first occurrence of a documented OR to the time of disease progression or death, whichever occurs first (up to approximately 41 months) ]
  • Percentage of Participants Who are Alive at Year 1 and 2 [ Time Frame: Years 1 and 2 ]
  • Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms as Determined by European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Score [ Time Frame: Baseline up to approximately 41 months ]
  • TTD in Patient-Reported Lung Cancer Symptoms as Determined by EORTC Quality-of-Life Questionnaire-Core Lung Cancer Module 13 (QLQ-LC13) [ Time Frame: Baseline up to approximately 41 months ]
  • Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale [ Time Frame: Baseline up to approximately 41 months ]
  • Percentage of Participants With Adverse Events [ Time Frame: Baseline up to approximately 41 months ]
  • Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab [ Time Frame: Baseline up to approximately 41 months ]
  • Maximum Observed Serum Concentration (Cmax) of Atezolizumab [ Time Frame: Arm A: Predose on Day (D) 1 of Cycle (Cy) 1,2,3,4,8,16 and every 8 cycles thereafter up to end of treatment (EOT) (approximately 41 months), 0.5 hours (h) post-infusion on D1 of Cy1,3, at 120 days after EOT (up to approximately 41 months) ]
    Predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.

  • Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion [ Time Frame: Arm A: Predose on D1 of Cy 1, 2, 3, 4, 8, 16 and every 8 cycles thereafter up to EOT (approximately 41 months), at 120 days after EOT (up to approximately 41 months) ]
    Predose samples will be collected on the same day of treatment administration.

  • Plasma Concentrations of Carboplatin [ Time Frame: Predose (same day of treatment administration), 5-10 minutes before end of carboplatin infusion, 1 h after carboplatin infusion (infusion duration=15 to 30 minutes) on D1 of Cy1,3 (1Cy=21 days) ]
  • Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel [ Time Frame: Predose (same day of treatment administration), 5-10 minutes before end of nab-paclitaxel infusion, 1 h after nab-paclitaxel infusion (infusion duration=30 minutes) on D1 of Cy1,3 (1Cy=21 days) ]
  • Cmax of Atezolizumab in Arm B Participants Who Received Atezolizumab During Maintenance Phase [ Time Frame: Arm B: Predose on D1 of Cy 1A,2A,3A,4A,8A,16A and every 8 cycles thereafter up to EOT (approximately 41 months), 0.5 h post-infusion on D1 of Cy1A,3A, at 120 days after EOT (up to approximately 41 months) ]
    Predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.

  • Cmin of Atezolizumab Prior to Infusion in Arm B Participants Who Received Atezolizumab During Maintenance Phase [ Time Frame: Arm B: Predose on D1 of Cy 1A,2A,3A,4A,8A,16A and every 8 cycles thereafter up to EOT (approximately 41 months), at 120 days after EOT (up to approximately 41 months) ]
    Predose samples will be collected on the same day of treatment administration.


Enrollment: 724
Actual Study Start Date: April 30, 2015
Estimated Study Completion Date: October 15, 2018
Estimated Primary Completion Date: May 1, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)
Participants will receive intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants will receive IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab will be administered to participants who are randomized to "Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin)" and to participants in "Arm B (Nab-Paclitaxel + Carboplatin)" who cross over at progression.
Other Name: MPDL3280A, RO5541267, Tecentriq
Drug: Carboplatin
Carboplatin will be administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
Drug: Nab-Paclitaxel
Nab-paclitaxel will be administered as IV infusion at a dose of 100 milligrams per square meter (mg/m^2) on Days 1, 8, and 15 of each 21-day cycle.
Active Comparator: Arm B (Nab-Paclitaxel+Carboplatin)
Participants will receive IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab will be administered to participants who are randomized to "Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin)" and to participants in "Arm B (Nab-Paclitaxel + Carboplatin)" who cross over at progression.
Other Name: MPDL3280A, RO5541267, Tecentriq
Drug: Carboplatin
Carboplatin will be administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
Drug: Nab-Paclitaxel
Nab-paclitaxel will be administered as IV infusion at a dose of 100 milligrams per square meter (mg/m^2) on Days 1, 8, and 15 of each 21-day cycle.
Drug: Pemetrexed
Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eastern Cooperative Oncology Group performance status of 0 or 1
  • Histologically or cytologically confirmed, Stage IV non-squamous NSCLC
  • Participants with no prior treatment for Stage IV non-squamous NSCLC
  • Previously obtained archival tumor tissue or tissue obtained from fresh biopsy at screening
  • Measurable disease, as defined by RECIST v1.1
  • Adequate hematologic and end organ function

Exclusion Criteria:

Cancer-Specific Exclusions:

  • Active or untreated central nervous system metastases
  • Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome

General Medical Exclusions:

  • Pregnant or lactating women
  • History of autoimmune disease
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted
  • Positive test for human immunodeficiency virus
  • Active hepatitis B or hepatitis C
  • Severe infection within 4 weeks prior to randomization
  • Significant cardiovascular disease
  • Illness or condition that interferes with the participant's capacity to understand, follow and/or comply with study procedures

Exclusion Criteria Related to Medications:

  • Prior treatment with cluster of differentiation 137 agonists or immune checkpoint blockade therapies, anti-programmed death-1, and anti-PD-L1 therapeutic antibodies
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02367781


  Hide Study Locations
Locations
United States, Arizona
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States, 85234
United States, Arkansas
Uni of Arkansas For Medical Sciences
Little Rock, Arkansas, United States, 72205
Highlands Oncology Group
Rogers, Arkansas, United States, 72758
United States, California
California Cancer Associates for Research & Excellence, Inc.
Encinitas, California, United States, 92008
Kaiser Permanente Oakland Medical Center
Oakland, California, United States, 94611
Kaiser Permanente Medical Center - Roseville
Roseville, California, United States, 95661
Kaiser Permanente - Sacramento Medical Center and Medical Offices
Sacramento, California, United States, 95825
Kaiser Permanente - San Francisco Medical Center
San Francisco, California, United States, 94115
Kaiser Permanente - San Jose Medical Center
San Jose, California, United States, 95119
Kaiser Permanente - San Leandro Medical Center
San Leandro, California, United States, 94577
Kaiser Permanente - Santa Clara
Santa Clara, California, United States, 95051
Kaiser Permanente - South San Francisco
South San Francisco, California, United States, 94080
Kaiser Permanente; Oncology Clinical Trials
Vallejo, California, United States, 94589
Kaiser Permanente - Walnut Creek
Walnut Creek, California, United States, 94596
United States, Connecticut
Eastern Connecticut Hematology and Oncology Associates; (ECHO)
Norwich, Connecticut, United States, 06360
United States, Florida
University of Miami School of Medicine - Sylvester at Deerfield
Deerfield Beach, Florida, United States, Suite 200
SCRI Florida Cancer Specialists South
Fort Myers, Florida, United States, 33916
Florida Hospital
Orlando, Florida, United States, 32803
Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building)
Saint Petersburg, Florida, United States, 33705
SCRI Florida Cancer Specialists East
Tallahassee, Florida, United States, 32308
United States, Georgia
University Cancer & Blood Center, LLC
Athens, Georgia, United States, 30607
Northwest Georgia Oncology Centers P.C.
Carrollton, Georgia, United States, 30117
Suburban Hematology / Oncology Associates
Lawrenceville, Georgia, United States, 30046
Southeastern Regional Medical Center, Inc.
Newnan, Georgia, United States, 30265
Lewis Hall Singletary Oncology Center
Thomasville, Georgia, United States, 31792
United States, Hawaii
On Care Hawaii, Inc.
Honolulu, Hawaii, United States, 96817
United States, Illinois
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Joliet Oncology-Hematology; Associates, Ltd.
Joliet, Illinois, United States, 60435
Loyola University Med Center
Maywood, Illinois, United States, 60153
Illinois Cancer Care
Peoria, Illinois, United States, 61615
Quincy Medical Group
Quincy, Illinois, United States, 62301
Southern Illinois University, Simmons Cancer Institute
Springfield, Illinois, United States, 62794
United States, Indiana
Fort Wayne Med Oncology & Hematology Inc
Fort Wayne, Indiana, United States, 46845
United States, Iowa
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52242-1083
Siouxland Hematology/Oncology
Sioux City, Iowa, United States, 51101
United States, Kentucky
Kentucky Cancer Clinic
Hazard, Kentucky, United States, 41701
Lahey Clinic Med Ctr
Lexington, Kentucky, United States, 02421
University of Louisville
Louisville, Kentucky, United States, 40202
Consultants in Blood Disorders & Cancer
Louisville, Kentucky, United States, 40207
United States, Louisiana
Ochsner Clinic Foundation
New Orleans, Louisiana, United States, 70121
United States, Maryland
Walter Reed National Military Medical Center
Bethesda, Maryland, United States, 20814
Center For Cancer and Blood Disorders
Bethesda, Maryland, United States, 20817
Fredrick Smith MD
Chevy Chase, Maryland, United States, 20815
United States, Massachusetts
Southcoast Health System
Fairhaven, Massachusetts, United States, 02719
United States, Michigan
Bronson Battle Creek
Battle Creek, Michigan, United States, 49016
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
CentraCare Health; Coborn Cancer Center
Saint Cloud, Minnesota, United States, 56303
United States, Mississippi
Hattiesburg Clinic
Hattiesburg, Mississippi, United States, 39401
Hematology and Oncology Associates at Bridgepoint
Tupelo, Mississippi, United States, 38801
United States, Nebraska
Southeast Nebraska Cancer Ctr
Lincoln, Nebraska, United States, 68510
United States, Nevada
Va Sierra Nevada Health Care System
Reno, Nevada, United States, 89502
United States, New Jersey
Englewood Hospital and Medical Center
Englewood, New Jersey, United States, 07631
Saint Barnabas Medical Center
Livingston, New Jersey, United States, 07039
Cancer Inst. of New Jersey
New Brunswick, New Jersey, United States, 08901
United States, New York
Clinical Research Alliance
Lake Success, New York, United States, 11042
Laura and ISAAC Perlmutter Cancer Center at NYU Langone.
New York, New York, United States, 10016
United States, North Carolina
Presbyterian Hospital
Charlotte, North Carolina, United States, 28204
Duke University Medical Center; Department of Medicine
Durham, North Carolina, United States, 27710
Carolina Oncology Specialists, PA - Hickory
Hickory, North Carolina, United States, 28602
W.G. Bill Hefner VA Medical Center
Salisbury, North Carolina, United States
United States, Ohio
The Christ Hospital
Cincinnati, Ohio, United States, 45219
Mark H. Zangmeister Center
Columbus, Ohio, United States, 43219
Oncology Hematology Care, Inc.
Hamilton, Ohio, United States, 45103
United States, Pennsylvania
Pinnacle Health
Harrisburg, Pennsylvania, United States, 17110
Lancaster General Hospital
Lancaster, Pennsylvania, United States, 17607
United States, Rhode Island
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
United States, South Carolina
Greenville Health System; Infectious Disease Associates
Greenville, South Carolina, United States, 29605
United States, Tennessee
University Oncology Associates
Chattanooga, Tennessee, United States, 37403
SCRI Tennessee Oncology Chattanooga
Chattanooga, Tennessee, United States, 37404
United States, Texas
SCRI The Center For Cancer and Blood Disorders
Denton, Texas, United States, 76210
University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Cancer Care Network of South Texas - SAT & BC
San Antonio, Texas, United States, 78217
Belgium
Cliniques Universitaires St-Luc
Bruxelles, Belgium, 1200
CHU Ambroise Paré
Mons, Belgium, 7000
Werken Glorieux VZW
Ronse, Belgium, 9600
GasthuisZusters Antwerpen
Wilrijk, Belgium, 2610
Canada, British Columbia
Bcca-Fraser Valley Cancer Centre
Surrey, British Columbia, Canada, V3V 1Z2
Canada, Ontario
Royal Victoria Regional Health Centre
Barrie, Ontario, Canada, L4M 6M2
William Osler Health Centre
Etobicoke, Ontario, Canada, M9V 1R8
Canada, Quebec
Cite de La Sante de Laval; Hemato-Oncologie
Laval, Quebec, Canada, H7M 3L9
Hôpital Maisonneuve - Rosemont
Montreal, Quebec, Canada, H1T 2M4
France
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, France, 33300
Institut Hospitalier Franco-Britannique; Cancerologie
Levallois-Perret, France, 92300
Fondation Hopital Saint Joseph;Cardiologie Clinique
Marseille, France, 13285
CHR Metz Thionville Hopital Notre Dame de Bon Secours
Metz, France, 57038
Clinique Clementville; Hopital De Jour
Montpellier, France, 34070
Centre D'oncologie de Gentilly; Service Oncologie Medicale
Nancy, France, 54100
Clinique Catherine de Sienne
Nantes, France, 44202
Hopital American de Paris (American Hospital of Paris)
Neuilly sur Seine, France, 92200
HOPITAL DE LA SOURCE; Service de Cardiologie, Point Jaune
Orleans, France, 45100
Hopital Pontchaillou
Rennes, France, 35033
Centre Hospitalier Regional Sud Reunion; Service de Pneumologie
Saint Pierre, France, 97448
Hopital d'Instruction des Armees de Begin
Saint-Mande, France, 94160
CHRU Nancy; Pneumologie
Vandoeuvre-lès-nancy, France, 54511
Centre Hospitalier Bretagne Atlantique Vannes
Vannes, France, 56017
Germany
Charite - Universitätsmedizin Berlin; Klinik fur Infektiologie und Pneumologie
Berlin, Germany, 13353
DIAKO Evangelische Diakonie Krankenhaus gGmbH
Bremen, Germany, 28239
Klinikum Chemnitz gGmbH
Chemnitz, Germany, 09116
Bezirksklinikum Obermain
Ebensfeld, Germany, 96250
Helios Klinikum Erfurt
Erfurt, Germany, 99089
St. Antonius Hospital
Eschweiler, Germany, 52249
Klinikum Esslingen GmbH
Esslingen Am Neckar, Germany, 73730
Malteser Krankenhaus St. Franziskus-Hospital
Flensburg, Germany, 24939
Krankenhaus Nordwest
Frankfurt am Main, Germany, 60488
Asklepios Fachkliniken GmbH
Gauting, Germany, 82131
SRH Wald-Klinikum Gera GmbH; Hautkrankheiten und Allergologie
Gera, Germany, 07548
Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie
Gerlingen, Germany, 70839
Universität Greifswald
Greifwald, Germany
Medizinische Hochschule Hannover
Hannover, Germany, 30625
Thoraxklinik Heidelberg gGmbH
Heidelberg, Germany, 69126
Fachklinik für Lungenerkrankungen
Immenhausen, Germany, 34376
St. Vincentius Kliniken Karlsruhe
Karlsruhe, Germany, 76137
Klinikum Kassel; Hautklinik
Kassel, Germany, 34125
Katholisches Klinikum Marienhof
Koblenz am Rhein, Germany, 56073
Klinikum Leverkusen GmbH
Leverkusen, Germany, 51375
Universitatsklinikum Schleswig-Holstein
Lubeck, Germany, 23538
Klinikum Mannheim GmbH Universitätsklinikum
Mannheim, Germany, 68167
Johannes Wesling Klinikum Minden
Minden, Germany, 32429
LMU Klinikum der Universitat Munchen
Munchen, Germany, 80337
Klinikum rechts der Isar der Technischen Universität München
Munchen, Germany, 81675
KH Maria Hilf Franziskushaus
Mönchengladbach, Germany, 41063
Universitätsklinikum Tübingen
Tuebingen, Germany, 72076
Universitatsklinikum Ulm; Klinik fur Innere Medizin II
Ulm, Germany, 89081
Praxis fur Haematologie und Internistische Onkologie
Velbert, Germany, 42551
Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie
Villingen-Schwenningen, Germany, 78052
Helios Klinik Wuppertal
Wuppertal, Germany, 42283
Dres. Christoph Maintz und Christiane Hinske
Wurselen, Germany, 52146
Hong Kong
Prince of Wales Hosp; Dept. Of Clinical Onc
Shatin, Hong Kong
Israel
Assaf Harofeh Medical Center
Beer Yaakov, Israel, 70300
Soroka University Medical Centre
Beer-Sheva, Israel, 84101
Hadassah Ein Karem Hospital; Oncology Dept
Jerusalem, Israel, 9112001
Meir Medical Center; Oncology
Kfar-Saba, Israel, 4428164
Galilee Medical Center
Nahariya, Israel, 22100
Rabin Medical Center
Petah Tikva, Israel, 4941492
Rambam Health Corporation; Oncology Institute
Rambam, Israel, 3525408
Kaplan Medical Center
Rehovot, Israel, 76100
Tel Aviv Sourasky Medical Ctr; Oncology
Tel Aviv, Israel, 6423906
Chaim Sheba Medical Center
Tel Hashomer, Israel, 52661
Italy
Ospedale Clinicizzato SS Annunziata
Chieti, Abruzzo, Italy, 66100
Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati
Avellino, Campania, Italy, 83100
Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia Medica
Napoli, Campania, Italy, 80131
Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
Napoli, Campania, Italy, 80131
Ospedale Di Macerata; Oncologia
Macerata, Marche, Italy, 62100
Ospedale Santa Maria Della; Misericordia Di Perugia; Farmacia Ospedaliera
Perugia, Umbria, Italy, 06129
Spain
Consorcio Hospitalario Provincial de Castellon
Castellon de la Plana, Castellon, Spain, 12002
Hospital Son Llatzer
Palma de Mallorca, Islas Baleares, Spain, 07198
Complejo Hospitalario Universitario A Coruña
A Coruña, La Coruña, Spain, 15006
Hospital Universitario de Torrejon
Torrejon de Ardoz, Madrid, Spain, 28850
Hospital Universitario de Canarias
S. Cristobal de la Laguna, Tenerife, Spain, 38320
Hospital Santa Creu i Sant Pau
Barcelona, Spain, 08025
Hospital de San Pedro de Alcantara
Caceres, Spain, 10003
Hospital Universitario Virgen de Las Nieves
Granada, Spain, 18012
Hospital General Universitario de Guadalajara
Guadalajara, Spain, 19002
Complejo Hospitalario de Jaen
Jaen, Spain, 23007
Hospital General Universitario de Valencia
Valencia, Spain, 46014
Hospital NisA 9 de Octubre
Valencia, Spain, 46015
Hospital Universitario Miguel Servet; Servicio Oncologia
Zaragoza, Spain, 50009
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT02367781     History of Changes
Other Study ID Numbers: GO29537
2014-003206-32 ( EudraCT Number )
First Submitted: February 13, 2015
First Posted: February 20, 2015
Last Update Posted: October 12, 2017
Last Verified: October 2017

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Paclitaxel
Atezolizumab
Albumin-Bound Paclitaxel
Carboplatin
Pemetrexed
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs
Enzyme Inhibitors
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors